Basilea Pharmaceutica AG Share Price Xetra
Equities
PK5
CH0011432447
Biotechnology & Medical Research
Sales 2024 * | 182M 202M 187M 16.88B | Sales 2025 * | 198M 219M 203M 18.32B | Capitalization | 465M 516M 478M 43.08B |
---|---|---|---|---|---|
Net income 2024 * | 26M 28.83M 26.73M 2.41B | Net income 2025 * | 29M 32.15M 29.81M 2.68B | EV / Sales 2024 * | 2.86 x |
Net Debt 2024 * | 56.76M 62.93M 58.36M 5.26B | Net Debt 2025 * | 12.51M 13.87M 12.86M 1.16B | EV / Sales 2025 * | 2.42 x |
P/E ratio 2024 * |
18.3
x | P/E ratio 2025 * |
16.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.61% |
Latest transcript on Basilea Pharmaceutica AG
Managers | Title | Age | Since |
---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 59 | 01/14/01 |
Adesh Kaul
DFI | Director of Finance/CFO | 50 | 01/09/01 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/18/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nicole Onetto
BRD | Director/Board Member | 71 | 27/17/27 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 01/22/01 |
Director/Board Member | 69 | 09/13/09 |
1st Jan change | Capi. | |
---|---|---|
+16.59% | 44.87B | |
-10.62% | 37.8B | |
+40.49% | 37.61B | |
+29.92% | 31.32B | |
-9.78% | 27.4B | |
+12.34% | 26.32B | |
+41.53% | 14.07B | |
+31.49% | 12.5B | |
-7.40% | 11.23B |